Does orlistat cause acute kidney injury?

被引：13

作者：

Beyea, Michael M. ^{[2
]}

Garg, Amit X. ^{[3
,4
]}

Weir, Matthew A. ^{[1
]}

机构：

[1] Univ Hosp, ALL 139A,339 Windermere Rd, London, ON N6A 5A5, Canada

[2] Univ Western Ontario, Kidney Clin Res Unit, London, ON, Canada

[3] Univ Western Ontario, Kidney Clin Res Unit, Dept Med, Div Nephrol, Toronto, ON, Canada

[4] Inst Clin Evaluat Sci, Toronto, ON, Canada

来源：

THERAPEUTIC ADVANCES IN DRUG SAFETY | 2012年 / 3卷 / 02期

关键词：

acute kidney injury; orlistat;

D O I：

10.1177/2042098611429985

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Orlistat is an inhibitor of gastric and pancreatic lipase with proven efficacy in the augmentation and maintenance of weight loss. Although its use has been limited by troublesome but benign gastrointestinal side effects, it has more recently been associated with acute kidney injury (AKI). In this review, we summarize orlistat's benefits and drawbacks and discuss the body of evidence supporting its role as a cause of AKI. Although we cannot yet draw an unequivocal causal link between orlistat and AKI, there is enough evidence to include orlistat exposure in the clinical assessment of patients with AKI.

引用

页码：53 / 57

页数：5

共 44 条

[1] Pelargonium sidoides for acute bronchitis:: A systematic review and meta-analysis [J].

Agbabiaka, Taofikat B. ;

Guo, Ruoling ;

Ernst, Edzard .

PHYTOMEDICINE, 2008, 15 (05) :378-385

[2] Orlistat and calcium oxalate crystalluria: An association that needs consideration [J].

Ahmed, Mohamed H. .

RENAL FAILURE, 2010, 32 (08) :1019-1021

[3] Agreement of expert judgment in causality assessment of adverse drug reactions [J].

Arimone, Y ;

Bégaud, B ;

Miremont-Salamé, G ;

Fourrier-Réglat, A ;

Moore, N ;

Molimard, M ;

Haramburu, F .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (03) :169-173

[4]

BEGAUD B, 1985, THERAPIE, V40, P111

[5] CAUSALITY ASSESSMENT OF ADVERSE REACTIONS TO DRUGS .2. AN ORIGINAL MODEL FOR VALIDATION OF DRUG CAUSALITY ASSESSMENT METHODS - CASE-REPORTS WITH POSITIVE RECHALLENGE [J].

BENICHOU, C ;

DANAN, G ;

FLAHAULT, A .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 1993, 46 (11) :1331-1336

[6] Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease [J].

Coca, Steven G. ;

Krumholz, Harlan M. ;

Garg, Amit X. ;

Parikh, Chirag R. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (11) :1377-1384

[7] WEIGHT-GAIN AS A RISK FACTOR FOR CLINICAL DIABETES-MELLITUS IN WOMEN [J].

COLDITZ, GA ;

WILLETT, WC ;

ROTNITZKY, A ;

MANSON, JE .

ANNALS OF INTERNAL MEDICINE, 1995, 122 (07) :481-486

[8] Rapidly progressive renal failure associated with successful pharmacotherapy for obesity [J].

Courtney, Aisling E. ;

O'Rourke, Declan M. ;

Maxwell, Alexander Peter .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (02) :621-623

[9]

DANAN G, 1993, GASTROEN CLIN BIOL, V17, pH22

[10] Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat - A randomized controlled trial [J].

Davidson, MH ;

Hauptman, J ;

DiGirolamo, M ;

Foreyt, JP ;

Halsted, CH ;

Heber, D ;

Heimburger, DC ;

Lucas, CP ;

Robbins, DC ;

Chung, J ;

Heymsfield, SB .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (03) :235-242

← 1 2 3 4 5 →